Rapid molecular investigation of multiple pathogens associated with meningitis and encephalitis from a single CSF sample.
Every year, more than 1.7 million people worldwide suffer from meningitis, and a substantial number die from bacterial meningitis. If timely and adequate treatment is not initiated, bacterial meningitis can be fatal within 24 hours — every minute counts. Rapid, sensitive aetiological detection directly determines the therapy chosen and the outcome.
Central nervous system infections present with fever, headache, vomiting, neck stiffness, confusion, seizures and altered consciousness. Bacterial causes (pneumococcus, meningococcus, H. influenzae, Listeria, Group B Streptococcus) are immediately life-threatening; viral causes range from self-limiting enteroviral meningitis to devastating HSV encephalitis; cryptococcal and tuberculous meningitis dominate in immunocompromised hosts. Risk groups include neonates, the elderly, the immunocompromised and the unvaccinated.
The conventional pathway is slow and often inconclusive. CSF culture takes up to 72 hours for a final result, has low sensitivity (around 25–30%) for fastidious organisms, and is strongly affected by sample transport and prior antibiotics. Serology takes at least 5–7 days, has low sensitivity, and is largely irrelevant to acute management decisions.
Conventional evaluation combines clinical assessment, CSF cell count and biochemistry, Gram stain and culture, antigen tests and serology. Each contributes evidence, but none delivers a rapid, comprehensive aetiological answer during the critical first hours.
The ID-Neurology Multiplex panel closes the early diagnostic gap: a single CSF sample is tested simultaneously against more than 35 bacterial, viral, fungal and mycobacterial targets, with results in approximately 5 hours — fast enough to guide the first treatment decisions.
Universal sterile container · Cap: White
Additive: None
Volume: 10–30 mL capacity
Collect aseptically; label immediately.
| Characteristic | Value | Source |
|---|---|---|
| Target count | More than 35 neurological pathogens detected simultaneously | ID Labs Specification |
| Turnaround time | Approximately 5 hours | ID Labs Specification |
| Sensitivity / specificity | High sensitivity and specificity claimed; performance is target-specific — data to be updated. | ID Labs Specification |
| Analytical / clinical performance | Performance characteristics: please contact ID Labs — data to be updated. | ID Labs Validated Performance |
Consider this panel for suspected meningitis/encephalitis, particularly when the patient has received antibiotics before lumbar puncture (molecular detection remains sensitive where culture fails), when tuberculous meningitis is suspected, and in immunocompromised patients with CNS symptoms. Culture and other CSF studies should still be performed in parallel.
| Conventional diagnosis vs ID-Neurology Multiplex | |||
|---|---|---|---|
| Feature | Culture | Serology | ID-Neurology Multiplex |
| Time to result | Up to 72 hours | 5–7 days | ≈ 5 hours |
| Sensitivity after antibiotics | Markedly reduced | Low (~20%) | Retained (nucleic acid detection) |
| Organism range per test | Bacteria only | Single pathogen | >35 bacteria, viruses, fungi, M. tuberculosis |
| Role in acute management | Confirmatory; enables AST | Limited | Guides early targeted therapy |
Kumar A, Roberts D, Wood KE, et al.
Critical Care Medicine · 2006 · Vol 34 · (6) · pp. 1589–1596
Landmark study showing that each hour of delay in effective antimicrobial therapy after the onset of septic shock is associated with a measurable decrease in survival — the evidence base for rapid diagnostics in sepsis.
World Health Organization
WHO Guidelines · 2021 (updated)
WHO recommendations on rapid molecular diagnostics for TB, including Xpert MTB/RIF and line probe assays, and their place within diagnostic algorithms. These are international guidelines; they do not constitute ID Labs validated performance data.
Scientific Reports (Nature) · 2024
Curated peer-reviewed / authoritative reference. Open the source link for the full text.
Microbiology Spectrum (ASM) · 2024
Curated peer-reviewed / authoritative reference. Open the source link for the full text.
Rapid detection of more than 30 sepsis-causing pathogens and their drug-resistance markers directly from whole blood.
Simultaneous detection of viruses, parasites and bacteria causing acute febrile illness and pyrexia of unknown origin from one sample.
Comprehensive viral and bacterial respiratory pathogen detection from swabs, sputum or BAL in a single multiplex assay.
Broad molecular screening for opportunistic viral, bacterial and fungal pathogens in transplant and immunocompromised patients.
Rapid syndromic testing tailored to febrile and seriously ill children, designed around small sample volumes.
Molecular detection of common sexually transmitted pathogens from a single urogenital specimen.
Panel configuration, specimen logistics and turnaround details on request.
Information on this page is educational and does not replace professional clinical judgment. Performance values are labelled by source (ID Labs Specification / ID Labs Validated Performance / Manufacturer Specification / Published Scientific Evidence). Molecular results must be correlated clinically and, where appropriate, confirmed by culture and phenotypic susceptibility testing.
